186 related articles for article (PubMed ID: 31680161)
1. Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study.
Jaeger VK; Tikly M; Xu D; Siegert E; Hachulla E; Airò P; Valentini G; Matucci Cerinic M; Distler O; Cozzi F; Carreira P; Allanore Y; Müller-Ladner U; Ananieva LP; Balbir-Gurman A; Distler JHW; Czirják L; Li M; Henes J; Jimenez SA; Smith V; Damjanov N; Denton CP; DelGaldo F; Saketkoo LA; Walker UA;
Rheumatology (Oxford); 2020 Jul; 59(7):1684-1694. PubMed ID: 31680161
[TBL] [Abstract][Full Text] [Related]
2. Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts.
Liem SIE; Boonstra M; le Cessie S; Riccardi A; Airo P; Distler O; Matucci-Cerinic M; Caimmi C; Siegert E; Allanore Y; Huizinga TWJ; Toes REM; Scherer HU; de Vries-Bouwstra JK;
Lancet Rheumatol; 2022 Oct; 4(10):e699-e709. PubMed ID: 38265968
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study.
Heijnen IA; Foocharoen C; Bannert B; Carreira PE; Caporali R; Smith V; Kumánovics G; Becker MO; Vanthuyne M; Simsek I; Bocelli-Tyndall C; Walker UA
Clin Exp Rheumatol; 2013; 31(2 Suppl 76):96-102. PubMed ID: 23101460
[TBL] [Abstract][Full Text] [Related]
4. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.
Foocharoen C; Suwannachat P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R;
Int J Rheum Dis; 2016 Mar; 19(3):312-20. PubMed ID: 25293362
[TBL] [Abstract][Full Text] [Related]
5. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis.
Iniesta Arandia N; Simeón-Aznar CP; Guillén Del Castillo A; Colunga Argüelles D; Rubio-Rivas M; Trapiella Martínez L; García Hernández FJ; Sáez Comet L; Egurbide Arberas MV; Ortego-Centeno N; Freire M; Marí Alfonso B; Vargas Hitos JA; Ríos Blanco JJ; Todolí Parra JA; Rodríguez-Carballeira M; Marín Ballvé A; Chamorro Fernández AJ; Pla Salas X; Madroñero Vuelta AB; Ruiz Muñoz M; Fonollosa Pla V; Espinosa G;
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):98-105. PubMed ID: 28980912
[TBL] [Abstract][Full Text] [Related]
6. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis.
Hamaguchi Y
J Dermatol; 2010 Jan; 37(1):42-53. PubMed ID: 20175839
[TBL] [Abstract][Full Text] [Related]
7. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
[TBL] [Abstract][Full Text] [Related]
8. Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort.
Zanatta E; Huscher D; Ortolan A; Avouac J; Airò P; Balbir-Gurman A; Siegert E; Matucci Cerinic M; Cozzi F; Riemekasten G; Hoffmann-Vold AM; Distler O; Gabrielli A; Heitmann S; Hunzelmann N; Montecucco C; Morovic-Vergles J; Ribi C; Doria A; Allanore Y;
Rheumatology (Oxford); 2022 Nov; 61(12):4786-4796. PubMed ID: 35348643
[TBL] [Abstract][Full Text] [Related]
9. Clinical and laboratory characteristics of systemic sclerosis patients with pulmonary arterial hypertension in China.
Huang J; Li M; Tian Z; Hsieh E; Wang Q; Liu Y; Xu D; Hou Y; Zhao J; Guo X; Lai J; Hu C; Song N; Sun Q; Sun Q; Zhang F; Zhao Y; Zeng X
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-115-21. PubMed ID: 25372797
[TBL] [Abstract][Full Text] [Related]
10. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.
Dick T; Mierau R; Bartz-Bazzanella P; Alavi M; Stoyanova-Scholz M; Kindler J; Genth E
Ann Rheum Dis; 2002 Feb; 61(2):121-7. PubMed ID: 11796397
[TBL] [Abstract][Full Text] [Related]
11. Relevance of clinical and autoantibody profiles in systemic sclerosis among Thais.
Foocharoen C; Watcharenwong P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R
Int J Rheum Dis; 2017 Oct; 20(10):1572-1581. PubMed ID: 28296274
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody.
Steen VD; Lucas M; Fertig N; Medsger TA
J Rheumatol; 2007 Nov; 34(11):2230-5. PubMed ID: 17937469
[TBL] [Abstract][Full Text] [Related]
13. Progression from suspected to definite systemic sclerosis and the role of anti-topoisomerase I antibodies.
Liem SIE; Neppelenbroek S; Fehres CM; Wevers BA; Toes REM; Allaart CF; Huizinga TWJ; Scherer HU; De Vries-Bouwstra JK
RMD Open; 2023 Feb; 9(1):. PubMed ID: 36746531
[TBL] [Abstract][Full Text] [Related]
14. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
15. The clinical relevance of autoantibodies in scleroderma.
Ho KT; Reveille JD
Arthritis Res Ther; 2003; 5(2):80-93. PubMed ID: 12718748
[TBL] [Abstract][Full Text] [Related]
16. Bibliographical study of the concurrent existence of anticentromere and antitopoisomerase I antibodies.
Kikuchi M; Inagaki T
Clin Rheumatol; 2000; 19(6):435-41. PubMed ID: 11147751
[TBL] [Abstract][Full Text] [Related]
17. Incidences and Risk Factors of Organ Manifestations in the Early Course of Systemic Sclerosis: A Longitudinal EUSTAR Study.
Jaeger VK; Wirz EG; Allanore Y; Rossbach P; Riemekasten G; Hachulla E; Distler O; Airò P; Carreira PE; Balbir Gurman A; Tikly M; Vettori S; Damjanov N; Müller-Ladner U; Distler JH; Li M; Walker UA;
PLoS One; 2016; 11(10):e0163894. PubMed ID: 27706206
[TBL] [Abstract][Full Text] [Related]
18. Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study.
Jaeger VK; Valentini G; Hachulla E; Cozzi F; Distler O; Airó P; Czirják L; Allanore Y; Siegert E; Rosato E; Matucci-Cerinic M; Caimmi C; Henes J; Carreira PE; Smith V; Del Galdo F; Denton CP; Ullman S; De Langhe E; Riccieri V; Alegre-Sancho JJ; Rednic S; Müller-Ladner U; Walker UA;
Arthritis Rheumatol; 2018 Nov; 70(11):1829-1834. PubMed ID: 29781588
[TBL] [Abstract][Full Text] [Related]
19. Cardiopulmonary Disease Development in Anti-RNA Polymerase III-positive Systemic Sclerosis: Comparative Analyses from an Unselected, Prospective Patient Cohort.
Hoffmann-Vold AM; Midtvedt Ø; Tennøe AH; Garen T; Lund MB; Aaløkken TM; Andreassen AK; Elhage F; Brunborg C; Taraldsrud E; Molberg Ø
J Rheumatol; 2017 Apr; 44(4):459-465. PubMed ID: 28089974
[TBL] [Abstract][Full Text] [Related]
20. Class II HLA associations with autoantibodies in scleroderma: a highly significant role for HLA-DP.
Gilchrist FC; Bunn C; Foley PJ; Lympany PA; Black CM; Welsh KI; du Bois RM
Genes Immun; 2001 Apr; 2(2):76-81. PubMed ID: 11393660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
